Halcion Web
Halcion Web
Halcion Web
Halcion
Oral Sedation
6/6/05
Copyright
Is
Halcion
the
Fred Quarnstrom, DDS
the
ugly FAGD,
Dirty Duck
FADSA,
FICD
Diplomate, American Dental Board of Anesthesionogy
or beautiful
Black
Swan?
Diplomate,
National Dental
Board of Anesthesiology
Certified, American Association of Dental Consultants
6/6/05
Copyright
6/6/05
Copyright
Would
you
please
try
to
relax.
6/6/05
Copyright
1:260,000
Physicians
1:248,000
1:143,000
1:598,000
Conscious sedation
1:1,000,000
6/6/05
Copyright
Conscious
Sedation
1. Protective reflexes intact
Patient can independently
and continuously maintain
an airway
Patient can respond
appropriately to verbal
commands 6/6/05
Deep
Sedation
2. Partial loss of
protective reflexes
Inability to
independently maintain
an airway
May not respond to
verbal commands
Copyright
General
Anesthesia
3. Loss of protective
reflexes
Inability to independently
maintain an airway
No pain sensation or reflex
withdrawal from stimuli
Total unconsciousness
Risks of Anesthesia
high
Deep
Sedation
Moderate
Sedation
Local
Anesthesia
Anxiolysis
low
N20
6/6/05
Copyright
General
Anesthesia
AGE VS ANESTHETIC-INDUCED,
CARDIAC ARREST / DEATH
incidence
rate
0.05
0.04
0.03
0.02
0.01
<1
6/6/05
Copyright
> 60
4
3
2
1
0
<10
11-20
6/6/05
Copyright
4
3
2
1
0
<10
11-20
6/6/05
Copyright
Resek,
Jayne, MS RN, Anesthesia
Today vol.11 No. 2 Fall 2000 p. 2
6/6/05
Copyright
Level 4 Anesthesia
Resek,
Jayne, MS RN, Anesthesia
Today vol.11 No. 2 Fall 2000 p. 2
6/6/05
Copyright
freq.
hyper
hypo
response
1 S.D.= 66%
2 S.D. = 95%
3 S.D. = 99.7%
6/6/05
Copyright
Chloral Hydrate
Response
100
ED50
50
LD50
Margin
of
Safety
0
6/6/05
Dose
Copyright
6/6/05
Copyright
Principals of Pharmacotherapy:
Pharmacokinetics
Pallasch, T.J. Anes. Progress 35:133-146 1988
Compartment Models
Simple one compartment model
all drugs spread uniformly through the body
Volume of Distribution
Apparent volume of distribution (Vd)
If Vd is small - drug is bound to plasma - little drug
will be in tissues - higher blood
concentrations
If Vd is large it will be widely distributed through the
tissues - but lower blood concentrations
6/6/05
Copyright
Principals of Pharmacotherapy:
Pharmacokinetics
Pallasch, T.J. Anes. Progress 35:133-146 1988
6/6/05
Copyright
Principals of Pharmacotherapy:
Pharmacokinetics
Pallasch, T.J. Anes. Progress 35:133-146 1988
I.V.
100
Distribution from
blood to tissue
distribution
(alpha phase)
75
50
Elimination via
liver and kidneys
Elimination
(beta phase)
25
0
0
10
10
6/6/05
Copyright
Principals of Pharmacotherapy:
Pharmacokinetics
Pallasch, T.J. Anes. Progress 35:133-146 1988
CHLORAL HYDRATE
CL
O H
CL C C H
CL
O H
chloral hydrate
6/6/05
CL
H
CL C C H
CL
O H
trichloroethanol
Copyright
CHLORAL HYDRATE
age
sex
15
O
22
O
weight
dose
procedure
reaction
drugs
115
3 g.
ex 3rd molars
vomit
narcan
dopamine
120
2.5g.
ex 3rd molars
problem
outcome
blood levels
6/6/05
epinephrine
c.a.
c.a.
revived
died
65 g/ml
71 g/ml
( normal 5 - 15 g/ml after 1 gm dose)
Copyright
dose
arrhythmia
c. a.
2
9
17
19
21
29
32
33
1.5
0.6
14
17.5
20
10
20
40
PVC
SVT
PVC, VT
PVC, Vfib
VT
PVC, VT
PVC, Vfib
PVC
no
no
no
yes
no
no
yes
yes
antiarrhythmia outcome
drug resistance
no
yes
yes
yes
no
yes
survived
survived
survived
survived
survived
survived
survived
died
6/6/05
Copyright
Response
100
ED50
50
LD50
Margin
of
Safety
Margin
of
Safety
0
6/6/05
Dose
Copyright
LD50
freq.
hyper
hypo
response
1 S.D.= 66%
2 S.D. = 95%
3 S.D. = 99.7%
6/6/05
Copyright
APPREHENSION CONTROL
sedation - mildly sleepy people are less
likely to feel fearful
barbiturates
alcohol - trichloroethanol (chloral hydrate)
anti anxiety medication
mephenesin
meprobamate - 1955
benzodiazepine
librium - 1960
valium - 1965
6/6/05
Copyright
TRANQUILIZERS
1945 Frank Berger - While attempting to
discover an antibacterial for penicillin
resistant bacteria, discovered mephenesin
which he noted quieted mice. An effect he
referred to as "tranquilization."
He developed a derivative meprobamate, which
turned out to be a sedative not a tranquilizer.
6/6/05
Copyright
BENZODIAZEPINE DRUGS
Roach was attempting to imitate the nonsedating
nonaddicting antianxiety actions attributed to
meprobamate.
( It turned out meprobamate
was a simple sedative.)
The goal was noble. The rational for the search
was flawed as such an agent did not exist.
to relieve anxiety
Snyde, Drugs and the Brain, N.Y.,Scientific American Library, 1986
6/6/05
Copyright
BENZODIAZEPINE TRANQUILIZERS
Leo Sternbach 1930 - Cracow, Poland developed quinazolines.
evaluated for Roach in 1955 saw no sedationturned chemicals over to Randall
Lowell Randall found an active agent
Sternbach reexamined chemical properties found it was not a quinazoline - named the
new class benzodiazepines
librium - 1960
valium - 1963
6/6/05
Copyright
BENZODIAZEPINE DRUGS
relieve anxiety
produce some drowsiness - patients became
tolerant to this effect in a few days
"vague uneasiness, generalized
fear and associated physical
symptoms of anxiety fade away."
tolerance develops
withdrawal occur
6/6/05
Copyright
GABA
Copyright
GABA Receptor
Cl
Cl
Cl
Cl
cell
wall
Cl
B
Cl
6/6/05
Copyright
Cl
Benzodiazepine
Copyright
Gaba
Cl
Cl
Cl
Cl
6/6/05
Cl
Copyright
Pharmacology
Compare
Compare to
to valium
valium
Absorption
Absorption
Half
Half life
life
Active
Active metabolites
metabolites
Structure-activity
Structure-activity relationship
relationship
Nitrogen
Nitrogen atom
atom prevents
prevents water
water solublity.
solublity.
Triazo
Triazo ring
ring alows
alows quick
quick metabolism
metabolism
Chlorine
Chlorine atom
atom is
is responsible
responsible for
for
potency.
potency.
Chlorine
Chlorine atom
atom is
is responsible
responsible for
for
benzodiazepine
benzodiazepine action.
action.
6/6/05
Copyright
Halcion - Triazolam
N
H C
3
Cl
Cl
6/6/05
Copyright
Triazolam Structure-Activity
N
triazo ring is
responsible for
ease of oxidation
N
H C
3
Cl
Cl is responsible
for potency
Cl
6/6/05
Cl is responsible for
benzodiazapine action
Copyright
Diazepam vs Triazolam
O
H C
3
H C
3
Cl
Cl
Cl
Diazepam
6/6/05
Triazolam
Copyright
Benzodiazepine Elimination
drug
major active
metabolites
alprazolam
1-2 hr.
12-15 hr.
6/6/05
Copyright
Diazepam vs Triazolam
drug
triazolam
1 - 2 hr.
major active
metabolites
6/6/05
Copyright
Benzodiazepine Elimination
drug
major active
metabolites
alprazolam
1-2 hr.
12-15 hr.
6/6/05
Copyright
Benzodiazepine Elimination
drug
major active
metabolites
alprazolam
1-2 hr.
12-15 hr.
6/6/05
Copyright
Benzodiazepine Elimination
drug
major active
metabolites
alprazolam
1-2 hr.
12-15 hr.
6/6/05
Copyright
Xanax -Alprazolam
Dosage 0.25-1.0 mg adults
Onset 1 hour
Durration 1-2 hours
2004 SW Dental Conference Joseph Giovannitti JR, DMD
QuickTime and a
TIFF (LZW) decompressor
are needed to see this picture.
6/6/05
Copyright
QuickTime and a
TIFF (LZW) decompressor
are needed to see this picture.
QuickTime and a
TIFF (LZW) decompressor
are needed to see this picture.
6/6/05
Copyright
6/6/05
Copyright
6/6/05
Copyright
6/6/05
Copyright
Effects
Interaction with the Gama Amino Butyric Acid
receptor complex.
Potentiates GABA.
Alters the Chloride ion channel to increase
frequency of their opening.
Interacts with the glycine receptors.
Alters opiate peptide concentrations.
5-HT decreases - a precursor of Seratonin.
6/6/05
Copyright
Effects
Central nervous system
Antianxiety, sedative-hypnotic,
anticonvulsant and skeletal muscle
relaxant
All depress CNS to some degree. These tend
to be more antianxiety as compared with
barbiturates and other sedative-hypnotics.
Depress the limbic system and areas of brain
associated with emotion and behavior
particularly the hippocampus and the
amygdaloid nucleus.
6/6/05
Copyright
Cardiovascular system
Benzodiazepines cause few alterations in
cardiac output or blood pressure when
administered intravenously to healthy
persons.
Slightly greater than normal doses cause slight
decreases in blood pressure, cardiac output,
and stroke volume in normal subjects and
patient with cardiac disease, but are not
usually clinically significant.
Triazolam did not affect cardovascular
dymanics in doses 4 to 8 times normal.
6/6/05
Copyright
Absorption
6/6/05
Copyright
Distribution
No difference in obese and normal patients.
Plasma potient binding at 89%. 49% to serum
proteins.
Crosses readily into central nervous system
because of high lipid solubility.
Crosses the placental barrier and milk of rats.
6/6/05
Copyright
Metabolism
Halcion is oxidized first pass in liver and lining
of gut by the cytochrome P450 monooxygenase system
The P450 is made up of many enzymes. The
majority of drug metabolism is by seven
enzymes, 1A2, 3A4, 2c8, 2C9/10, 2C19, 2C19,
2D6, 2F1.
Halcion is metabolized by the 3A4 enzyme.
The presence or absence of an enzyme can be
idiosyncratic or associated with certain patient
subsets6/6/05
Copyright
Metabolism
The absence of an enzyme can be
idiosyncratic or associated with certain patient
subsets
CYP 2D6: 2-10% of the total population
5-10% of Caucasians 6% of AfroAmericans
0-1% of Asians
CYP 2C19: 18-25% of Afro-Americans and
Asians
2-5% of Caucasians
Copyright
Elimination
Half life averages 1.2 to 3.3 hours.
Slower at night.
Longer - elderly - lower liver
oxidixing capacity.
No change with kidney dialysis.
Slower with cirrhosis.
91% eliminated in urine
9% in feces within 72 hr.
6/6/05
Copyright
Benzodiazepine Elimination
CNS. conc.
drug
blood brain
barrier
plasma conc.
plasma binding
liver
portal circulation
(metabolism)
excretion
6/6/05
fat
fatpartition
stores
time
1hr.
Copyright
6 hr.
1 d.
6 d.
Bioavailability
Fraction of
unchanged
drug reaching
the systemic
circulation after
administration
by any route
6/6/05
Oral Dose
IV Dose
Target Organ
Portal
Circulation
Systemic
Circulation
Cytochrome
Excretion Copyright
P450metabolism
Inhalation
N2O
Copyright
Cardiovascular system
Benzodiazepines cause few alterations in
cardiac output or blood pressure when
administered intravenously to healthy persons
Slightly greater than normal doses cause slight
decreases in blood pressure, cardiac output and
stroke volume in normal subjects and patients
with cardiac disease, but are not usually
clinically significant.
Triazolam did not affect cardovascular dynamics
in doses 4 to 8 times normal.
6/6/05
Copyright
Contraindications to Traizolam
absolute
relative
known
known hypersensitivity
hypersensitivity
lack
lack of
of knowledge
knowledge
inability
inability to
to initiate
initiate resuscitation
resuscitation
myasthemia
myasthemia gravis
gravis
glaucoma
glaucoma
first
first trimester
trimester
lactation
lactation
concurrent
concurrent CNS
CNS depressants
depressants
Cimethadine
Cimethadine (tagamet)
(tagamet)
Erythromycin
Erythromycin
Isoniazid
Isoniazid
6/6/05
pediatric
pediatric patients
patients
geriatric
geriatric patients
patients
psychiatric
psychiatric patients
patients
no
no FDA
FDA approval
approval for
for
dental
dental sedation
sedation
Copyright
Patient Assessment
ASA Classification American Society of Anesthesiologists
ASA I:
ASA II:
ASA III:
ASA IV:
ASA V:
ASA E:
6/6/05
normal healthy
mild systemic disease does
not effect the way the live
severe systemic disease
effects the way they live
incapacitating systemic
disease
moribund, 24 hours to live
emergency
Copyright
Patient Assessment
Much the same as for doing dentistry
Cardiovascular Disease
Pregnancy benzodiazepines are known
teratogens
Elderly
Patients on Steroids
6/6/05
Copyright
Cardiovascular Disease
Hypertension
Ischemic heart disease
Valvular heart disease
Congestive heart disease
Dysrhythmia
6/6/05
Copyright
Cardiovascular Disease
Hypertension
Systolic
<140
140
160-200
200 &/or
6/6/05
Diastolic
<90
&/or 90-95
Effect on Treatment
none
none: reassess BP next 2
appt.
&/or 95-115 reassess in 5 min.,
refer to MD
>115
reassess in 5 min., refer to
MD immediately
Copyright
Cardiovascular Disease
Hypertension Protocol
Vital signs
Stress reduction
Chairside manner
Profound Local Anesthesia
Conscious sedation
Limit epinephrine to 0.04 mg. 2
cartridges - 1:100,000 epi.
Retraction cord with epi. ???
6/6/05
Copyright
Cardiovascular Disease
Hypertension
Ischemic heart disease
stable
Treatment?
Yes?
Valvular heart disease
Congestive heart disease
Dysrhythmia
6/6/05
Copyright
unstable
No
Cardiovascular Disease
Hypertension
Ischemic heart disease
stable
unstable
Treatment?
Yes?
No
Valvular heart disease
Consider SBE prophylaxis
Medical consultation
Congestive heart disease
Medical Consultation
Dysrhythmia
6/6/05
Copyright
Cardiovascular Disease
Hypertension
Ischemic heart disease
stable
unstable
Treatment?
Yes?
No
Valvular heart disease
Consider SBE prophylaxis
Medical consultation
Congestive heart disease
Medical Consultation
Dysrhythmia
6/6/05
Copyright
Cardiovascular Disease
Hypertension
Ischemic heart disease
stable
unstable
Treatment?
Yes?
No
Valvular heart disease
Consider SBE prophylaxis
Medical consultation
Congestive heart disease
Medical Consultation
Dysrhythmia
6/6/05
Copyright
Cardiovascular Disease
Dysrhythmia
Vital signs
Stress reduction
Chairside manner
Profound local anesthesia
Conscious sedation
Limit epi to 0.04 mg. 2 cartridges
1:100,000
No epi. in retraction cord
6/6/05
Copyright
Elderly
Physiologic changes with age
Concomitant disease
Polypharmacy review medication list
Drug interactions
Decrease initial dose
6/6/05
Copyright
Patients on Steroids
Physiologic release
20-30 mg of cortisol daily
equivalent to:
20-30 mg of hydrocortisone daily
5-7.5 mg. Of prednisone daily
Coverage is required if:
Stressful procedure
On physiologic dose, at least 1 week in
past year
Double daily dose or 100 mg I.M. Hydrocortisone
6/6/05
Copyright
Metabolism
The absence of an enzyme can be
idiosyncratic or associated with certain patient
subsets
CYP 2D6: 2-10% of the total population
5-10% of Caucasians 6% of AfroAmericans
0-1% of Asians
CYP 2C19: 18-25% of Afro-Americans and
Asians
2-5% of Caucasians
Copyright
Drug interactions
Cimethedine - for ulcer treatment
Erythromycin - an antibiotic
Isoniazid - an antitubercular agent
Reduce the first pass liver clearance by
decreased metabolism and reduction in
hapatic blood flow. Due to decrease in
cytochrome P450-mediated oxidatative
system.
6/6/05
Copyright
Halcion Study
Patients
173
Treatments
269
Age
Sex
male
female
Weight
6/6/05
54
119
Copyright
75
6/6/05
Copyright
6/6/05
Copyright
6/6/05
Copyright
AGE
count
30
20
10
10
6/6/05
20
30
40
Copyright
50
60
70
AGE
count
30
20
10
10
20
30
40
50
60
70
6/6/05
Copyright
Apprehension Level
terrified
panicked
very afraid
afraid
tense
nervous
calm
start
6/6/05
30 min.
60 min
Copyright
finish
6/6/05
Copyright
6/6/05
Copyright
Amnesia
100%
% of patients
remembering
symbol
80%
60%
40%
20%
pre
med
6/6/05
30
min
60
min
Copyright
mid
end
procedure
Blood pressure
systolic
160
140
120
100
80
60
diastolic
mmHg.
Copyright
90
90
pulse
rate
SaO2
sd +
-2
80
pre
opt.
6/6/05
15
min
30
min
45
min
Copyright
60
min
6/6/05
Copyright
n = 100
.25
suggested dose
minimum dose
.125
0
6/6/05
50
100
150
tended to sleep
good sedation
200
250
300
difficult but possible
uncontrolable
Copyright
ADA Guidelines
Except for unusual circumstances, the maximum
recommended dose (mrd) shall not be exceded.
Only one dose can be given. You may not titrate for effect.
Inaccordwiththisparticulardefinition,titrationoforalmedication
forthepurposesofsedationisunpredictable.Repeateddosingof
orallyadministeredsedativeagentsmayresultinanalterationofthe
stateofconsciousnessbeyondtheintentofthepractitioner.Exceptin
unusualcircumstancestheMaximumRecommendedDose(MRD)of
anoralmediationshouldnotbeexceeded
The FDA stated there is no mrd for halcion used as an oral
sedative.
6/6/05
Copyright
no sedation
.625
.5
.375
n = 100
.25
suggested dose
minimum dose
.125
0
50
100
150
tended to sleep
good sedation
200
250
300
difficult but possible
uncontrolable
6/6/05
With
newCopyright
ADA Guideline
no sedation
.75
.625
.5
.375
.25
suggested dose
.125
minimum dose
0
50
100
150
tended to sleep
good sedation
200
250
300
difficult but possible
uncontrolable
6/6/05
With
newCopyright
ADA Guideline
Dose
Dose
of = 0.25mg + 0.125mg
Halcion
weight - 40
70
(weight in pounds)
If at 30 minutes the patient notices NO
sedation and the dentist observes NO Weight vs. Dose of Halcion
sedation, half the original dose is
administered sublingually.
.75
.625
.5
.375
n = 100
.25
suggested dose
minimum dose
.125
0
6/6/05
50
100
150
tended to sleep
good sedation
Copyright
200
250
300
difficult but possible
uncontrolable
I.V.
100
Distribution from
blood to tissue
distribution
(alpha phase)
75
50
Elimination via
liver and kidneys
Elimination
(beta phase)
25
0
0
10
10
6/6/05
Copyright
Principals of Pharmacotherapy:
Pharmacokinetics
Pallasch, T.J. Anes. Progress 35:133-146 1988
active
conc.
halcion
Population study of triaazolam
pharmacokinetics B.J.Clin.Pharmc (1986)
22, 639-642
Triazolam pharmacodynamics in obesity, J. Clin
Psychopharmacol Vol 15/no3, June 1995
time
6/6/05
2 Copyright
3
First dose
time
6/6/05
2 Copyright
3
halcion effect
sedation
level
1
time in hours
6/6/05
Copyright
Flumazenol
COOCH CH
3
N
H C
3
C H3
N
H C
3
Cl
Cl
Cl
F lumazenol
6/6/05
Triazolam
Copyright
Flumazenil
ethyl 6 - fluoro - 6, 6 - dihydro - 5 methyl - 6 - oxo - 4h - imidazo
(l,5-a) (1,4) benzodiazepine - 3 carboxylate
6/6/05
Copyright
Dose
.007 and .014 mg/kg.
Lethal dose in mice and rats is 62.5 and 125 mg
/ kg.
One study suggested lethal dose is 3000 times
theraputic dose.
It has been tested up to 200 mg. IV and oral. In
the case of oral dosages only 18% is active
as it is oxidized in first pass through the liver
6/6/05
Copyright
6/6/05
Copyright
Half life
At 54 minutes (.7 to 1.3 hr. 50 min. average) is
less than midazolam and valium so you may
see some rebound.
Worked within 2 to 5 minutes.
One author saw no improvment after 15
minutes.
Another showed improvment at 15, 30 but not 60
minutes.
1 mg. will last for about 2 hours.
6/6/05
Copyright
halcion
without
reversal
time
6/6/05
3
Copyright
Reversal of
Triazolam by
Romazicon,
IV reversal
SL reversal
Flumazenil,
Much effect
An unpublished
from the
needle stick
study
6/6/05
Min.
5 10
Copyright
15
20
sedation
level
time in minutes
6/6/05
Copyright
sedation
level
nitrous oxide effect
15
time in minutes
6/6/05
30
45
Copyright
60
sedation
level
halcion effect
1
time in hours
6/6/05
Copyright
halcion effect
sedation
level
1
time in hours
6/6/05
Copyright
17
4
45
20
8
Joynt,
Brian, Journal of Analytical
Toxicology, vol.17 May/June 1993 p171-177
6/6/05
Copyright
17
4
45
20
8
17
4
45
20
8
Qs Recommendations
This refers only to the use of halcion
MRD is for use as a sleep aid - elderly with no monitoring
ED60 equals about the LD5 of chloral hydrate.
Copyright
Qs Recommendations
Administered in the office
assistant in the room
Dr. in the office
Monitoring
Pulse oximeter monitoring - constant
BP monitoring (q. 15 min.)
No multiple drugs Single drug plus nitrous oxide OK.
Staff and Dentist must have BLS every year.
The Dentist should be trained and current in
the use of nitrous oxide.
6/6/05
Copyright
Solution
Research
Education
Education
Good courses will drive out
Or cause bad courses to be altered.
It is the responsibility of the ADA to educate
and publish when so many are using a drug in
6/6/05
Copyright
potentially
dangerous techniques.
6/6/05